Mindwalk Holdings Corp. · NASDAQ:HYFT
Mindwalk — ImmunoPrecise Antibodies — Q1 FY2024 Earnings Presentation
17 slides from Mindwalk's earnings presentation, Sep 14, 2023
Slide 1: FY24 Q1 Earnings Presentation
FY24 Q1 Earnings Presentation SEPTEMBER 14, 2023 | ir.ipatherapeutics.com | NASDAQ: IPA, TSXV: IPA
Slide 2: Disclosures
Disclosures Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilitie
Slide 3: Fiscal Year 2024 Q1 Business Update
Fiscal Year 2024 Q1 Earnings Call Fiscal Year 2024 Q1 Business Update ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of BioStrand, BV. LENSai and HYFTS
Slide 4: Board of Directors development
Fiscal Year 2024 Q1 Earnings Call Spotlight on business Board of Directors development Chris Buyse Barry Springer Dirk Witters Extensive capital markets experience Wealth of experience in therapeutic Seasoned advisor in healthcare with executive leadership and board antibody discovery and developmen
Slide 5: Key financial highlights: Continuing strong momentum
Fiscal Year 2024 Q1 Earnings Call Spotlight on business Key financial highlights Continuing strong momentum • Second back-to-back and new quarterly record revenues • Consolidated revenue grew +21.3% YOY • Newly expanded protein manufacturing facility - growth of +44.0% YOY • Higher quarterly net inc
Slide 6: Sales highlights
Fiscal Year 2024 Q1 Earnings Call Spotlight on business Sales highlights Record sales revenue +21.3% year-over-year Q1 growth Antibody discovery signed sales orders • Year-over-year Q1 increase of +59% • June's total $3.51 million: +125% over Q1 FY23 • July’s total $1.56 million: +64% over Q1 FY23 i
Slide 7: Advancing the combination of wet lab + in silico
Fiscal Year 2024 Q1 Earnings Call Spotlight on business Scientific advancements Advancing the combination of wet lab + in silico • Service packages update • Active participation at the Festival of Biologics • Service offerings adaptation • B cell discovery developments • Engaging with the bispecific
Slide 8: IPA's in silico-driven de-risking platform
Fiscal Year 2024 Q1 Earnings Call IPA’s in silico-driven de-risking platform Enabling more informed lead nomination and increasing the value of therapeutics with in-depth risk mitigation More Integrated in silico-driven de-risking Characteristics Less Improving the value of therapeutic leads through
Slide 9: Advancing the combination of wet lab + in silico
Fiscal Year 2024 Q1 Earnings Call Spotlight on business Scientific advancements Advancing the combination of wet lab + in silico • Service packages update • Active participation at the Festival of Biologics • Service offerings adaptation • B cell discovery developments • Engaging with the bispecific
Slide 10: Operational Updates: Strategically built for growth
Fiscal Year 2024 Q1 Earnings Call Spotlight on business Operational Updates Strategically built for growth • AI integration and growth • Platform capabilities • In silico immunogenicity analysis • LENSai platform’s new feature ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibodies LTD. A
Slide 11: Fiscal Year 2024 Q1 Financial Update
Fiscal Year 2024 Q1 Earnings Call Fiscal Year 2024 Q1 Financial Update ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of BioStrand, BV. LENSai and HYFT
Slide 12: Trends in Revenue and Gross Profit
Fiscal Year 2024 Q1 Earnings Call Trends in Revenue and Gross Profit Revenue Gross Profit $5,688 $4,588 $4,689 $2,795 $2,506 $2,479 Three Months Ended Three Months Ended Three Months Ended July 31, 2021 July 31, 2022 July 31, 2023 All values listed in thousands and CAD. Ir.ipatherapeutics.com | NASD
Slide 13: Changes in Operating Expenses
Fiscal Year 2024 Q1 Earnings Call Changes in Operating Expenses All values listed in thousands and CAD. Ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary
Slide 14: Changes in Other Income (Expense)
Fiscal Year 2024 Q1 Earnings Call Changes in Other Income (Expense) All values listed in thousands and CAD. Ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidi
Slide 15: Changes in Net Loss
Fiscal Year 2024 Q1 Earnings Call Changes in Net Loss All values listed in thousands and CAD. Ir.ipatherapeutics.com | NASDAQ:IPA ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary of BioStra
Slide 16: Changes in Cash Balance
Fiscal Year 2024 Q1 Earnings Call Changes in Cash Balance July 31, 2023 $6,813 April 30, 2023 $8,366 ($197) ($249) ($405) ($702) Cash used in Cash used in Cash used in Effect of FX Operating Activities Investing Activities Investing Financing All values listed in thousands and CAD. Ir.ipatherapeutic
Slide 17: FY 2024 Q1 Earnings Call
FY 2024 Q1 Earnings Call The HUB of Date: September 14, 2023 | ir.ipatherapeutics.com | NASDAQ: IPA, TSXV: IPA Biotherapeutic Intelligence™ ©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD. BioStrand is an independently operating subsidiary
ImmunoPrecise Antibodies — Q1 FY2024 Earnings Presentation on 6ix